A previous study reported that reduced TPX2 expression in HCC-infiltrating CD8 + T cells and downregulated TPX2 could restrict the anticancer effect of CD8 + T cells in HCC, whereas such antitumor activity could be enhanced by TPX2 overexpression (Wang et al. 2022a). Here, TPX2 is linked to hepatocellular carcinoma.